ATH 25.0% 0.5¢ alterity therapeutics limited

Parkinson's drug heart effects.

  1. 5,826 Posts.
    lightbulb Created with Sketch. 143
    May be of interest pivalde. ITCI(market cap $1.06b) Have just applied for their first NDA(new drug application) for their schizophrenia drug ITI-007. What is maybe of more interest here is their Parkinson's P1 program for ITI-214. It looks like through inhibition of PDE2 and PDE3 ITI-214 can block the breakdown of cAMP and cGMP to re-establish normal function in these conditions, to treat heart failure(in dogs). I am not sure if PBT434 can inhibit PDE.
    https://parkinsonsnewstoday.com/201...s-therapy-may-also-treat-heart-failure-study/

    There was also some interesting info last year on preclinical process of ITI-007 concerning animal toxicity study results.
    [Thinly traded micro cap Intra-Cellular Therapeutics (NASDAQ:ITCI) jumps 33% premarket on increased volume in response to its announcement that the FDA has agreed that the toxicity from schizophrenia candidate lumateperone observed in nonclinical studies in animal models is not relevant to humans considering their distinctive metabolic pathways.]
    https://seekingalpha.com/news/32912...toxicity-lumateperone-shares-ahead-33-percent
    Imagine that.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
46 57663299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 56205001 43
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 29/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.